Introduction
Chronic GVHD is a major late complication of SCT. Chronic GVHD has received only a fraction of the research attention received by acute GVHD. Recent changes in SCT practice have made it imperative to better define and treat this disorder. The incidence of chronic GVHD is increasing because of the increased use of donor-lymphocyte infusions and PBSCs, increasing age of transplant recipients and use of more alternative donors.
One of the major obstacles to chronic GVHD research is the lack of standardized staging and response criteria. Although some of the studies on therapies for chronic GVHD have been retrospective, 1,2 others, studying sirolimus, 3 rituximab, 4 pentostatin 5 and photopheresis, 6 have been prospective clinical trials. Unfortunately, there are no validated, standardized response criteria. Thus, it has been impossible to judge the severity of chronic GVHD of patients entered into these trials or to compare the responses to these new therapies.
It has been very difficult to develop grading and response criteria. This has resulted in each centre using different criteria. The National Institute of Health (NIH) has recently tackled the issue of lack of uniform, validated grading and response criteria at a Consensus Conference on chronic GVHD. There have been some recent publications showing that the NIH Consensus staging criteria have applicability: specifically, the severity under the new classification correlates with worse survival and acute features (that is, overlap syndrome) portend worse survival. [7] [8] [9] These studies were, by necessity, performed with retrospective grading.
One of the major objectives of this conference was to develop response criteria for clinical trials in chronic GVHD. After extensive discussion, a set of response criteria for clinical trials in chronic GVHD was proposed by the NIH Consensus Conference. 10 Validation of these criteria is currently an area of active collaborative research (S Lee, personal communication). However, it will require years of follow-up of current patients for prospective validation of these recommendations to be available. Although there has been some progress with validation of staging criteria, little has been done with the response criteria. We have recently completed a trial of pentostatin in the treatment of steroid-refractory chronic GVHD. Extensive data (including the percent body-surface-area (BSA) of rash, superficial sclerosis and deep sclerosis) were prospectively collected during the trial. From these, grades and responses using the newly proposed NIH criteria were generated. The performance of the NIH scale 10 was compared with the scale used during the study. 5 We were interested in determining: (a) the scores and the change in response score during treatment using the NIH scale during the course of the trial; and (b) comparing the NIH scale to the scale used during the trial: in particular, were there elements of one of the scales that seemed to be more predictive of ultimate response? One of the main purposes of carrying out this analysis is that it could potentially identify areas within the NIH scale that may eventually need fine-tuning. As the skin was the most commonly affected organ for patients in the trial, this report examined only cutaneous responses.
Patients and methods
This was an open-label phase II trial evaluating a new agent (pentostatin) in the treatment of steroid-refractory chronic GVHD. All assessments for the trial were performed by experienced chronic GVHD investigators (GBV or DJ at JH and DJ at CMH). Details of the trial, including overall responses and individual organ responses, have been reported. 5 A total of fifty-eight patients were enrolled on this trial. Fifty patients are reported in this paper. Six patients were not included because they were treated at Children's Memorial Hospital, and percent BSA at each assessment was not recorded. Two patients had only their initial assessment and no follow-up and thus were not evaluable for change. Subjects were assessed for response every 3 months using a scale that included oral examination, oral symptoms, bilirubin and skin findings (lichenoid/ erythema, skin scleroderma and fascial). Stability and/or response (improvement in at least one point in a domain) was needed to continue on study therapy. Table 1 shows the evaluation tool as it pertains to the three skin domains. Table 2 shows the pertinent skin domains of the NIH scale. These values were recorded at each interval visit (included in a form that included an extensive evaluation) for the fifty subjects. The percent BSA recorded at each visit was recorded using both markings on a figure to show the areas involved, and an estimate of the percentage body area involved based on the rules of nine.
For the purpose of this analysis, domain responses were calculated for each scale. For the Hopkins scale, a response in each domain (skin lichenoid/erythematous lesions, scleroderma and fascial) constituted an improvement of at least one point. An overall response occurred if there was improvement in at least one of the three domains, with no worsening in any domain. For the retrospective use of the NIH Consensus Scale (which is a global chronic GVHD tool from which we extracted the skin component), a response in each domain (erythematous rash of any sort, moveable sclerosis, non-moveable sclerosis/fasciitis) was determined. Assignment of domain complete or partial response was made using Appendix C (http://www.asbmt. org/GvHDForms) of the NIH Consensus for chronic GVHD. 10 For this analysis, complete or partial domain response using the NIH scale constituted a response. Furthermore, an overall response was attained in this scale if there was response in at least one of the three domains, with no worsening in any domain. For the purposes of our comparative analyses, we equated 'skin scleroderma' from the Hopkins scale with 'moveable sclerosis' from the NIH scale and 'fascial' with 'non-moveable sclerosis'. Ulcer(s):* select the largest ulcerative lesion, and measure its largest dimension in cm, and mark location of ulcer Location:______________________ Largest dimension:______________ *Ulcer diameter was excluded as a criterion of interest in this study.
Response rates for each scale were calculated as percentages. Agreement between the two scales was summarized using the percentage of cases showing a response or no response on both scales, as well as the percentage of cases where the scales gave discordant results. The final response was correlated between the two scales using a kappa statistic.
Results
At the initial visit, the 50 subjects had the following median BSA level of involvement using NIH criteria: skin lichenoid/erythematous lesions 19% (0-100%), moveable sclerosis 20% (0-100%) and non-moveable sclerosis 20% (0-100%). Using the 1-4 Hopkins scale, the subjects had the following median level of involvement: lichenoid 1 (0-4), scleroderma 1(0-4) and fascial 2(0-3). At study entry, 33 patients had lichenoid involvement, 35 had scleroderma and 35 had fascial involvement. At the 3-month evaluation, 19 had lichenoid, 33 had scleroderma and 32 had fascial involvement. Twenty-five patients received therapy beyond the 3-month evaluation and returned for follow-up. At the completion of the study (final assessment), eight had lichenoid, 15 had scleroderma and 17 had fascial involvement. The first analysis examined the correlation between the Hopkins scale and the NIH Consensus Scale. We looked at the level of agreement in skin domain response and overall response at 3 months (n ¼ 50 patients) and at final assessment (n ¼ 25). The timing of final assessment varied from patient to patient, and ranged from 6 months to 23 months. Figure 1 depicts the level of agreement between the two scales in response in the three skin domains, and the overall skin response, at 3 months. Fifty subjects made it to this initial assessment. As seen in Figure 1 , there is relatively close agreement between the two scales in all domains, as indicated by the sum of percentages in the first two bars of each graph. Agreement was highest in the lichenoid domain (86%), and lowest in the scleroderma/moveable sclerosis and fasciitis/non-moveable sclerosis domains (76%). Specifically, non-agreement in these domains mostly represented patients graded as responders by the Hopkins scale and as non-responders by the NIH scale. The level of agreement for overall response at this visit was high (78%). Fourteen percent of patients were called responders by the NIH scale and non-responders by the Hopkins scale; only 8% were called responders by the Hopkins tool and nonresponders by the NIH tool. Figure 2 depicts the level of agreement between the two scales in the three skin domains, and the overall skin response, at the final trial assessment in the 25 patients who continued therapy beyond 3 months. There was a high level of agreement in the lichenoid domain (88%), but it was lower in the scleroderma/moveable sclerosis domain (72%) and even lower in the fasciitis/non-moveable sclerosis domain (64%). As in the 3-month time point, most of the non-agreement in the last two domains came from patients considered as responders by the Hopkins tool, and as non-responders by the NIH tool. For fasciitis/non-moveable sclerosis response, there was a 36% level of overall disagreement. Twenty-eight percent (that is, 3/4 of the disagreement) came from patients being called responders by the Hopkins scale and non-responders by the NIH scale.
The level of agreement for overall response at the final visit was high (80%). Only 8% of patients were called responders by the NIH scale and non-responders by the Hopkins scale; and 12% were called responders by the Hopkins tool and non-responders by the NIH tool. A kappa statistic correlating the response at the final visit for all 50 patients had the value of 0.42 (95% confidence interval of 0.17-0.67).
The second analysis consisted of determining the tempo of response for each of the skin domains, and for overall skin response, using both scales. Specifically, are we able to identify response at 3 months in patients who are ultimately considered responders? Figure 3 depicts the percent of patients having response in each domain as well as overall, by scale. Patients are subdivided as to whether they had only one follow-up visit (3 months, N ¼ 25) or additional follow-up visits (N ¼ 25). In the latter case, the responses at the 3-month assessment and the final assessment are shown.
Both scales performed similarly for lichenoid/rash response. For patients followed beyond 3 months, a significant response (44% for the Hopkins scale and 56% for the NIH scale) was detected by both scales at 3 months, and this response persisted to the final assessment for those patients who had additional follow-up. Therefore, response to rash occurred early and was picked up equally well by both tools. For scleroderma/moveable sclerosis response, the Hopkins scale seemed to be more predictive of eventual response. Specifically, for patients with follow-up beyond 3 months, the response in this domain was 44 and 52% using the Hopkins scale, and 20 and 40% using the NIH scale, at 3 months and at final assessment, respectively. The same findings applied to fasciitis/non-moveable sclerosis response. Specifically, for patients with follow-up beyond 3 months, the response in this domain was 60 and 68% using the Hopkins scale, and 36 and 48% using the NIH scale, at 3 months and at final assessment, respectively. Finally, both scales performed similarly for overall response, with an overall response in the 70% range at 3 months, and in the 80% range at final assessment, for those patients with follow-up more than 3 months.
Discussion
These analyses illustrate several very interesting points. First, in chronic GVHD trials, it is imperative to have response criteria established before the entry of the first patient. This study has shown that relatively minor differences in response scales did have a significant impact on the response evaluation. This would affect both the ability of the patient to continue on the trial and the resulting response rate. To be able to compare and interpret results from clinical trials, a standardized, validated scale is needed. There is currently an NIH-funded study that is attempting to validate the NIH Consensus Criteria (S Lee, personal communication). Until this study is completed, we would urge investigators to use the NIH Consensus Criteria instead of centre-based criteria in prospective clinical trials, as this allows for standardization and comparisons of trials. Second, this analysis illustrates the difficulty in defining skin involvement in chronic GVHD. For erythematous rash, the use of BSA is very standard. The Hopkins criteria translate the percent BSA to a unique point from 0 to 4, depending on the percentage; and the NIH criteria uses the raw percent to calculate response. Not surprisingly, the level of agreement when it comes to response for erythematous rashes is extremely high. There is less agreement between the scales in the assessment of sclerodermatous skin involvement. This has been a difficult area to evaluate clinically. The two scales approached response differently. In the Hopkins scale, improvement was judged by the degree of sclerosis (that is, the thickness and mobility). The NIH scale relied on the distribution, irrespective of the degree of thickness. For example, a patient whose skin was formerly fixed skin that could now be pinched would be considered a responder in the Hopkins scale but not in the NIH scale if the percent of skin involved remained constant. This discrepancy is illustrated by the analysis in Figure 1 of both 'scleroderma/moveable sclerosis' and 'fasciitis/non-moveable sclerosis' responses. The majority of the discrepancy at 3 months in these domains is accounted for by classifying patients as responders by the Hopkins scale and as non-responders by the NIH scale. Interestingly, this discrepancy is less apparent in the analysis of overall skin response. The predominant improvement at 3 months was in the lichenoid/erythematous rashes (for which response definitions are similar for the Hopkins and NIH scales), which therefore dominated the overall response.
Defining the response in sclerodermatous GVHD has proven extremely difficult. This is hardly surprising; there has been little accord in defining response in systemic sclerosis. Improvement or worsening has been based on fairly subjective criteria in the physical examination resulting in considerable intra-observer variability. The best solution to this problem would be an objective way of documenting the extent of sclerosis. Until such a way is found, one approach to this problem has been to teach evaluators so that they are using as close as possible criteria for staging and response. Still, using skin 'softening' introduces significant subjectivity. There are currently efforts to develop more sensitive and objective measures such as skin thickness magnetic resonance imaging and joint range-of-motion. Other scales that address skin texture also need further validation, such as the Vienna scale 11 and the Rodnan total skin score.
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In this study, two investigators (GBV and DJ) gauged the extent of the sclerotic skin changes. One investigator (DJ) has been extensively involved in teaching the new NIH criteria. The Hopkins scale used 'skin scleroderma' and 'fascial' as different domains. The NIH scale is proposing the use of 'moveable sclerosis' and 'non-moveable sclerosis,' the latter including fasciitis. We equated 'skin scleroderma' from the Hopkins scale with 'moveable sclerosis' from the NIH scale and 'fascial' with 'nonmoveable sclerosis.' This brings up a limitation of our study, which is that the scales are not directly comparable because of 'retrospective fitting'. A prospective trial would be required to truly compare the two scales.
In summary, this is the first attempt to use the NIH response criteria using data collected in real time from an actual clinical trial. It is important to note that the NIH tool has been designed as a global chronic GVHD tool and not specifically for an isolated domain such as the skin. Therefore, although it is appropriate to extract one component from the instrument for this validation study, it should not be used in this manner in a clinical trial. We compared two response scales-the scale used during the conduct of the trial and the NIH Consensus Scale for grading of skin response in a completed trial for chronic GVHD. Owing to the lower frequency of other organs involved with GVHD in patients enrolled in the trial, there were insufficient data points to compare the two scales in other organs.
This comparison showed that the two scales produced different domain response rates but similar overall response-emphasizing the need to have one validated response tool for use in chronic GVHD. The two scales could potentially yield very different overall response rates in patient populations with less erythematous lesions. There was more disparity in the scales in the measurement of sclerosis than in that of erythema. The Hopkins scale, which used skin softening, was more predictive early on for future responses in sclerosis. This suggests that an early assessment of skin softening may be important when designing a clinical trial to decide if there is activity of that particular agent in chronic GVHD. The assessment of sclerosis using the NIH criteria may need refinement, especially for use in exploratory, short-term trials. However, it is also possible that the Hopkins scale may be too sensitive. Of the five patients who were responders by the Hopkins scale, but not by the NIH scale, three did well in the long term and were tapered off immunosuppression. Of the nine patients who were NIH but not Hopkins-scale responders, one patient did well in the long term. This suggests that both scales need further use and refinement to accurately identify those patients who will do well. Until the NIH criteria are validated, we encourage others to examine any trial data they have that could help shed further light on this problem, specifically for sclerosis and for the other organs, where we were unable to perform a comparison of tools.
